C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

Slides:

Advertisements

Similar presentations

Supplementary Figure S1Wang et. al. Supplementary Figure S1: (a) Purity of transferred Tconv. Tconv (CD4 + CD45RB hi CD25 ) were sorted from the spleen.

Advertisements

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.

Supplementary Data shLuc sh   sh  179 shLuc sh   sh  179 Asyn Noco 2.1% 6.1% 2.4% 16.5%11.4%1.1% 5.9%3.9%2.5% 52.5%10.0%4.9%

Supplementary Materials. Supplementary Figure S1. The effect of the freezing/thawing procedure on CD15 and CD33 marker staining on human PBMCs. Prostate.

Supplemental Figures CAN Sahu et al.. Fig Supplementary S1 Figure S1. Chemotherapy agents generate PAF-R agonist formation in human SK23MEL melanoma.

min 30 min 45 min 60 min KDa Figure S1. SDS-PAGE of supernatant after incubation in digestion buffer. L. monocytogenes.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.

Date of download: 6/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Quantification and Functional Characterization of.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro Tamás Mészáros, MSc,

Date of download: 10/22/2017 Copyright © ASME. All rights reserved.

Figure 4. The protective effect of F

Patient Characteristic

TNFR1 and TNFR2 are expressed on native human ASM but activation of TNFR1 mediates ICAM-1 expression in human ASM cells. TNFR1 and TNFR2 are expressed.

IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity.

Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis.

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCθ and ERK pathways by Gilles Despouy, Marjorie Joiner, Emilie Le Toriellec,

by Kumudha Balakrishnan, William G. Wierda, Michael J

Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells by Sergey Krysov, Samantha Dias, Alex Paterson, C.

TNF enhances dose‐dependent cell death following doxorubicin‐induced DNA damage with minimal affect on dose‐dependent cell‐cycle arrest. TNF enhances dose‐dependent.

Volume 17, Issue 2, Pages (February 2010)

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia by Christine Le Roy, Pierre-Antoine Deglesne, Nathalie.

Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach Jeremiah.

Supplemental Figure % annexin V-stained cells mean A

SUPPLEMENTAL TABLE 1. Cell cycle profiles of HeLa cells treated

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Volume 138, Issue 1, Pages (January 2010)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

by Silvia Mele, Stephen Devereux, Andrea G

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Consequences of reducing SF3B2 expression.

Supplementary Figure 2 Shiota et al.

Volume 15, Issue 6, Pages (June 2012)

Roth et al, Supplementary Figure 1

Table S1: Characteristics of the cancer patients

In Vitro Keratinocyte Dissociation Assay for Evaluation of the Pathogenicity of Anti- Desmoglein 3 IgG Autoantibodies in Pemphigus Vulgaris Ken Ishii,

FLC treatment results in an increase in ploidy in a significant fraction of cells. FLC treatment results in an increase in ploidy in a significant fraction.

IL-12 affects Dermatophagoides farinae–induced IL-4 production by T cells from pediatric patients with mite-sensitive asthma Takeshi Noma, MD, PhD, Izumi.

Figure 4 Purified IgG from DEM patients induces loss of cytoskeleton organization in live human oligodendroglial MO3.13MOG+ cells Purified IgG from DEM.

Lapatinib reduces IGF-I signaling in trastuzumab-resistant cells.

Figure 2 C5B3 prevented AQP4-IgG–mediated CDC without affecting AQP4-IgG binding to AQP4 C5B3 prevented AQP4-IgG–mediated CDC without affecting AQP4-IgG.

A B Supplementary Figure 1

Anifrolumab does not elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. Anifrolumab does.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Figure 1. Effects of Gal-4 on apoptosis and proliferation of monocytes

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

Bcl-2 and bcl-xL Antisense Oligonucleotides Induce Apoptosis in Melanoma Cells of Different Clinical Stages Robert A. Olie, Christoph Hafner, Renzo Küttel,

Vaginal CD11c+ DCs from IL-17A−/− mice are impaired in potentiating Th17 responses because of diminished IL-1β production. Vaginal CD11c+ DCs from IL-17A−/−

TSA-mediated changes in cell cycle inhibitor proteins.

Lamellarin D induces cell death through a Fas-independent pathway.

LY induces cytotoxicity in hMECs via inhibition of Akt/p70S6K kinase activities. LY induces cytotoxicity in hMECs via inhibition of Akt/p70S6K.

Tipifarnib combined with bortezomib induces cell death in diverse multiple myeloma and AML cell lines. Tipifarnib combined with bortezomib induces cell.

Uptake of TEX by DCs in vivo.

Immunologic and pharmacokinetic studies.

SY-1425 induces maturation in RARA-high AML

Influence of ASGR2 expression on survival.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. A,

Fig. 2 BX795 is nontoxic to HCE cells at therapeutic concentration.

Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.

B-cell development in young Pax5+/− mice.

ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits migration. ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits.

E2 induces IL-17–producing γδ+ T cells in the FGT

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Lack of innate immune cell and receptor triggering by Adjuplex.

**** *** * **** **** *** Shahriary et al.- Supplementary Figure 4 (a)

Presentation transcript:

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient sera are not significantly affected by Binet stage. The concentrations of complement components of the classical cascade and CLL patient sera exhaustion were compared against Binet stage of disease at the point of sample collection. Mean of individual patient samples is shown. A. C1q levels compared against clinical stage (n=42). B. C2 levels compared against clinical stage (n=46). C. C3 levels compared against clinical stage (n=53). D. C4 levels compared against clinical stage (n=53). E. CLL patient sera exhaustion was also compared against clinical stage (n=54). An unpaired t test was performed, with no significant difference observed between the mean complement levels or the level of CLL sera exhaustion and the different clinical stages of disease.

C1q g/L C2 g/L C3 g/L C4 g/L A. C. E. B. D. Supplementary Figure 2 - Middleton et al. NR Supplementary Figure 2. Complement concentrations in CLL patient sera are not significantly affected by poor prognosis cytogenetics. The concentrations of complement components of the classical cascade and CLL patient sera exhaustion were compared against the different CLL cytogenetic subgroups normal/13q, 11q del and 17p del. Mean of individual patient samples is shown. A. C1q levels compared against cytogenetic subgroups (n=36). B. C2 levels compared against cytogenetic subgroups (n=39). C. C3 levels compared against cytogenetic subgroups (n=45). D. C4 levels compared against cytogenetic subgroups (n=45). E. CLL patient sera exhaustion was also compared against cytogenetic subgroups (n=40). An unpaired t test was performed, with no significant difference observed between the mean complement levels or the level of CLL sera exhaustion and the different cytogenetic subgroups.

C1q g/L C2 g/L C3 g/L C4 g/L A. C. E. B. D. Supplementary Figure 3 - Middleton et al. NR Supplementary Figure 3. Complement concentrations in CLL patient sera are not significantly affected by ZAP-70 status. The concentrations of complement components of the classical cascade and CLL patient sera exhaustion were compared against the ZAP-70 status. Mean of individual patient samples is shown. A. C1q levels compared against ZAP-70 status (n=37). B. C2 levels compared against ZAP-70 status (n=41), 25% ZAP-70 positive CLL patients are deficient in C2 compared to 10% that are ZAP-70 negative. C. C3 levels compared against ZAP-70 status (n=48). D. C4 levels compared against ZAP-70 status (n=48). E. CLL patient sera exhaustion was also compared against ZAP-70 status (n=40). An unpaired t test was performed, with no significant difference observed between the mean complement levels or the level of CLL sera exhaustion and ZAP-70 status.

Supplementary Figure 4 - Middleton et al. A. B. Supplementary Figure 4. CLL patient sera shows significantly reduced CDC activity when used for a second time. HG3 cells were treated with 20 μg/ml OFA and then incubated with 50% CLL patient sera or NHS and the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead cells is expressed relative to untreated control. A. Induction of CDC from CLL patient sera for the first set of OFA-treated HG3 cells was assessed by PI staining (NHS, n=12; CLL, n=48). Serum that caused ≥40% CDC was used for secondary CDC. B. Sera from the first set of OFA-treated HG3 cells were removed from the cells and used for a second time to determine the CDC activity induced on fresh HG3 cells treated with 20 μg/ml OFA (2° use) (NHS, n=12; CLL, n=48). p values were determined by an unpaired t-test (** p<0.01).

Supplementary Figure 5 - Middleton et al. A. B. C. Supplementary Figure 5. CLL sera exhaustion also negatively correlates with C4 levels. Figure 4 demonstrates that complement component C2 concentration shows a significantly negative correlation with CLL patient sera exhaustion. Complement C4 concentration also displays a significant negative correlation with CLL sera exhaustion levels but to a lesser degree. A. C1q levels in CLL patient sera were compared against CLL patient sera exhaustion (n=43). Linear regression was applied to obtain values for r 2, and p value, B. C3 levels in CLL patient sera were compared against CLL patient sera exhaustion (n=47). Linear regression was applied to obtain values for r 2, and p value, C. C4 levels in CLL patient sera were compared against CLL patient sera exhaustion (n=43). Linear regression was applied to obtain values for r 2, and p value,

i. C2 deficientii. C4 deficient iii. C2/C4 deficientiv. C2/C3/C4 deficient A. B. Supplementary Figure 6 - Middleton et al. Supplementary Figure 6. CLL sera exhaustion in complement deficient serum can be restored with the addition of C2 alone. CLL sera that had complement deficiencies in C2, C3 and/or C4 were supplemented with C2 (50 μg/ml), C4 (700 μg/ml) or both C2/C4 (25 μg/ml/350 μg/ml respectively), before being used to induce CDC in HG3 cells treated with 20 μg/ml OFA (1° use). After the incubation period, sera was removed and re-challenged with HG3 cells treated with 20 μg/ml OFA (2° use). Percentage of dead cells is relative to untreated control. A. (i) Representative CLL patient serum sample deficient in C2 alone. (ii) Representative CLL patient serum sample deficient in C4 alone. (iii) Representative CLL patient serum sample deficient in C2 and C4. (iv) Representative CLL patient serum sample deficient in C2, C3 and C4. B. CLL sera (n=16) that exhibited high levels of serum exhaustion were supplemented with C2 (n=14), C4 (n=9), C2 and C4 combined (n=8) Mean cell death + SEM are shown. p value were obtained by paired t test (* p<0.05, ** p<0.01, *** p<0.001).